These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 32542785)

  • 1. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
    Stebbing J; Krishnan V; de Bono S; Ottaviani S; Casalini G; Richardson PJ; Monteil V; Lauschke VM; Mirazimi A; Youhanna S; Tan YJ; Baldanti F; Sarasini A; Terres JAR; Nickoloff BJ; Higgs RE; Rocha G; Byers NL; Schlichting DE; Nirula A; Cardoso A; Corbellino M;
    EMBO Mol Med; 2020 Aug; 12(8):e12697. PubMed ID: 32473600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
    Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Peterson D; Damsky W; King B
    J Am Acad Dermatol; 2020 Jun; 82(6):e223-e226. PubMed ID: 32278797
    [No Abstract]   [Full Text] [Related]  

  • 7. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
    Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
    J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
    Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
    Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
    Praveen D; Puvvada RC; M VA
    Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
    David P; Hen O; Ben-Shabbat N; Macleod T; Amital H; Watad A; McGonagle DG
    RMD Open; 2024 May; 10(2):. PubMed ID: 38796180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
    Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathogenesis and treatment of cytokine storm in COVID-19.
    Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
    Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
    Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J
    Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529
    [No Abstract]   [Full Text] [Related]  

  • 14. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
    Solimani F; Meier K; Ghoreschi K
    Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
    Cingolani A; Tummolo AM; Montemurro G; Gremese E; Larosa L; Cipriani MC; Pasciuto G; Liperoti R; Murri R; Pirronti T; Cauda R; Fantoni M;
    Infection; 2020 Oct; 48(5):767-771. PubMed ID: 32642806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.
    Dang C; Lu Y; Chen X; Li Q
    Front Immunol; 2021; 12():650708. PubMed ID: 33927721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
    Spinelli FR; Conti F; Gadina M
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Baricitinib in the treatment of SARS-CoV-2 infection].
    Gutiérrez-Lorenzo M; Cuadros-Martínez CM
    Rev Esp Quimioter; 2020 Aug; 33(4):294-295. PubMed ID: 32583654
    [No Abstract]   [Full Text] [Related]  

  • 20. Thoughts on COVID-19 and autoimmune diseases.
    Askanase AD; Khalili L; Buyon JP
    Lupus Sci Med; 2020; 7(1):e000396. PubMed ID: 32341791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.